ADC Therapeutics to Present at Upcoming Investor Conferences
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September. The company will be represented by CEO Ameet Mallik at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring a virtual fireside chat at 7:00 a.m. ET.
2. 10th Cantor Global Healthcare Conference 2024 on September 18, 2024, with a fireside chat scheduled from 11:30-12:00 p.m. ET.
Live webcasts of both presentations will be accessible through the company's website, with replays available for approximately 30 days after each event.
Details
News Market Reaction – ADCT
The recorded move for ADCT in the trading session of this news was -5.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September:
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9, 2024
Presentation Time: 7:00 a.m. ET
Format: Virtual Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
10th Cantor Global Healthcare Conference 2024
Date: September 18, 2024
Presentation Time: 11:30-12:00 p.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit the Company website at adctherapeutics.com and follow us on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.